BCRX - BioCryst Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Durham,
United States
Type: Equity
BCRX price evolution
BCRX
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $80.2 | $86.13 | $112.45 | |
| Short term investments | $193.62 | $252.22 | $278.34 | |
| Net receivables | $72.46 | $68.76 | $60.59 | $56.95 |
| Inventory | $7.56 | $28.98 | $29.78 | $28.68 |
| Total current assets | $427.13 | $363.46 | $447.1 | $495.97 |
| Long term investments | $64.32 | |||
| Property, plant & equipment | $7.42 | $7.66 | $7.83 | $7.91 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $108.96 | $20.79 | $20.99 | |
| Total investments | $257.93 | $252.22 | $278.34 | |
| Total assets | $491.25 | $472.42 | $467.89 | $516.96 |
| Current liabilities | ||||
| Accounts payable | $13.48 | $7.79 | $11.91 | $20.89 |
| Deferred revenue | ||||
| Short long term debt | $31.68 | $28.76 | $26.21 | |
| Total current liabilities | $153.57 | $129.06 | $119.92 | $149.99 |
| Long term debt | $798.18 | $818.96 | $824.14 | $822.5 |
| Total noncurrent liabilities | $818.96 | $824.14 | $822.5 | |
| Total debt | $850.64 | $852.9 | $848.71 | |
| Total liabilities | $959.82 | $948.02 | $944.06 | $972.49 |
| Shareholders' equity | ||||
| Retained earnings | -$1743.24 | -$1729.21 | -$1716.54 | -$1681.16 |
| Other shareholder equity | $2.29 | $0.56 | $0.77 | $1.34 |
| Total shareholder equity | -$475.61 | -$476.17 | -$455.53 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $112.45 | $306.24 | $507.73 | $274.35 |
| Short term investments | $278.34 | $119.54 | $3.21 | $28.24 |
| Net receivables | $56.95 | $50.6 | $29.41 | $8.65 |
| Inventory | $28.68 | $27.53 | $15.79 | $7.04 |
| Total current assets | $495.97 | $516.5 | $566.14 | $323.8 |
| Long term investments | $18.08 | $6.83 | ||
| Property, plant & equipment | $7.91 | $15.42 | $8.71 | $7.11 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $20.99 | $33.5 | $22.02 | $10.91 |
| Total investments | $278.34 | $137.62 | $10.04 | $28.24 |
| Total assets | $516.96 | $550 | $588.15 | $334.71 |
| Current liabilities | ||||
| Accounts payable | $20.89 | $14.36 | $27.81 | $18.71 |
| Deferred revenue | $1.22 | $1.42 | $0.15 | |
| Short long term debt | $26.21 | $2.37 | $1.82 | $31.18 |
| Total current liabilities | $149.99 | $105.51 | $103.72 | $105.65 |
| Long term debt | $822.5 | $733.28 | $591.42 | $248.32 |
| Total noncurrent liabilities | $822.5 | $739.08 | $591.42 | $248.32 |
| Total debt | $848.71 | $741.45 | $593.24 | $279.5 |
| Total liabilities | $972.49 | $844.6 | $695.14 | $353.98 |
| Shareholders' equity | ||||
| Retained earnings | -$1681.16 | -$1454.62 | -$1207.5 | -$1023.44 |
| Other shareholder equity | $1.34 | $0.03 | $0.18 | $0 |
| Total shareholder equity | -$455.53 | -$294.6 | -$106.99 | -$19.26 |
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $117.08 | $92.76 | $93.4 | |
| Cost of revenue | $1.39 | $1.64 | ||
| Gross Profit | $113.86 | $91.37 | $91.76 | |
| Operating activities | ||||
| Research & development | $46.49 | $70.05 | ||
| Selling, general & administrative | $59.36 | $64.38 | ||
| Total operating expenses | $106.17 | $105.86 | $134.43 | |
| Operating income | -$14.49 | -$42.67 | ||
| Income from continuing operations | ||||
| EBIT | -$10.51 | -$38.58 | ||
| Income tax expense | $0.59 | $0.36 | -$1.43 | |
| Interest expense | -$21.14 | $24.51 | $24.58 | |
| Net income | ||||
| Net income | -$14.03 | -$35.38 | -$61.73 | |
| Income (for common shares) | -$35.38 | -$61.73 | ||
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $331.41 | $270.83 | $157.17 | $17.81 |
| Cost of revenue | $4.66 | $6.59 | $7.26 | $1.68 |
| Gross Profit | $326.75 | $264.23 | $149.91 | $16.14 |
| Operating activities | ||||
| Research & development | $216.57 | $253.3 | $208.81 | $122.96 |
| Selling, general & administrative | $213.89 | $159.37 | $118.82 | $67.93 |
| Total operating expenses | $430.46 | $412.67 | $327.63 | $190.89 |
| Operating income | -$103.71 | -$148.44 | -$177.72 | -$174.76 |
| Income from continuing operations | ||||
| EBIT | -$117.99 | -$145.29 | -$122.52 | -$168.31 |
| Income tax expense | $0.31 | $2.73 | $2.25 | |
| Interest expense | $108.24 | $99.09 | $59.29 | $14.5 |
| Net income | ||||
| Net income | -$226.54 | -$247.12 | -$184.06 | -$182.81 |
| Income (for common shares) | -$226.54 | -$247.12 | -$184.06 | -$182.81 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$12.67 | -$35.38 | -$61.73 | |
| Operating activities | ||||
| Depreciation | $0.32 | $0.31 | $0.42 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $13.17 | $13.65 | $16.49 | |
| Total cash flows from operations | -$1.37 | -$53.68 | -$8.92 | |
| Investing activities | ||||
| Capital expenditures | -$0.15 | -$0.23 | -$0.55 | |
| Investments | -$2.29 | $28.99 | -$27.92 | |
| Total cash flows from investing | $34.8 | -$2.45 | $28.76 | -$28.47 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.25 | $1.69 | $0.16 | |
| Net borrowings | -$0.4 | -$0.39 | -$1.17 | |
| Total cash flows from financing | -$1.74 | -$1.97 | -$1.05 | -$3.17 |
| Effect of exchange rate | $0.37 | -$0.14 | -$0.34 | $0.52 |
| Change in cash and equivalents | -$13.38 | -$5.93 | -$26.32 | -$40.04 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$226.54 | -$247.12 | -$184.06 | -$182.81 |
| Operating activities | ||||
| Depreciation | $1.66 | $1.44 | $0.78 | $0.75 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $55.62 | $44.7 | $34.64 | $14.79 |
| Total cash flows from operations | -$95.14 | -$161.85 | -$142.16 | -$137.22 |
| Investing activities | ||||
| Capital expenditures | -$2.17 | -$1.35 | -$2.38 | -$0.51 |
| Investments | -$129.33 | -$126.89 | $18.19 | -$6.34 |
| Total cash flows from investing | -$131.5 | -$128.24 | $15.8 | -$6.86 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $8.68 | $14.96 | $65.79 | $95.72 |
| Net borrowings | $25.98 | $73.07 | $293.87 | $192.16 |
| Total cash flows from financing | $32.48 | $88.03 | $359.67 | $302.7 |
| Effect of exchange rate | $0.36 | $0.57 | $0.07 | |
| Change in cash and equivalents | -$193.79 | -$201.5 | $233.39 | $158.63 |
News
Fundamentals
| Market cap | $1.64B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 207.12M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 34.98% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | -2.13 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.78 |
| Quick ratio | 2.73 |